Some question the safety of AstraZeneca's just-launched DARE-19 study testing whether the type 2 diabetes drug dapagliflozin will reduce adverse outcomes of COVID-19.
from WebMD Health https://ift.tt/2yhv09Y
Some question the safety of AstraZeneca's just-launched DARE-19 study testing whether the type 2 diabetes drug dapagliflozin will reduce adverse outcomes of COVID-19.
0 comments:
Post a Comment